Clinical trial to investigate nitric oxide treatment of Covid-19

accreditation

Doctors at the University of Alabama at Birmingham (UAB) are enrolling patients in an international clinical trial to find out if inhaled nitric oxide benefits those with Covid-19 who have severely damaged lungs.

Right now, there are no approved treatments for the illness caused by the new coronavirus. A severe form of lung failure called acute respiratory distress syndrome is the leading cause of death in Covid-19.

When lungs are failing, air is received by some parts of them but not others. Nitric oxide is a gas that improves blood flow in areas of the lungs that are getting air, increasing the amount of oxygen in the blood stream.

Nitric oxide also reduces the workload of the right side of the heart, which is under extreme stress during lung failure.

Destroys potential toxins

Along with being used to treat failing lungs, nitric oxide has been found to have antiviral properties against coronaviruses. That was shown during the 2002–2003 SARS outbreak, which was caused by a coronavirus similar to the one that causes Covid-19.

Any Covid-19 patient in UAB's intensive care unit who is using a ventilator to breathe may qualify for the study.

"This trial will allow the sickest Covid-19 patients at UAB access to a rescue therapy that may have antiviral benefits in addition to improving the status of lungs," Dr Vibhu Parcha said in a university news release. He's a research fellow in the Division of Cardiovascular Disease.

"In humans, nitric oxide is generated within the blood vessels and regulates blood pressure, and prevents the formation of clots and also destroys potential toxins," said Dr Pankaj Arora, an assistant professor of cardiovascular disease. His team plans to study the cardiovascular effects of high-dose inhaled nitric oxide as part of the primary clinical trial.

READ | SA expert cautions on coronavirus treatment

READ | Coronavirus | The chloroquine debate: Two experts weigh in

READ | This malaria drug could be a treatment option for the new coronavirus - what does the research say?

Image credit: iStock
We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Results
Nkosazana Dlamini-Zuma has got it in the bag
7% - 828 votes
I foresee a second term for Cyril Ramaphosa
83% - 9503 votes
Don’t discount a Zweli Mkhize win
10% - 1114 votes
Vote
Rand - Dollar
18.01
-0.0%
Rand - Pound
20.18
-0.4%
Rand - Euro
17.65
-0.1%
Rand - Aus dollar
11.54
+0.1%
Rand - Yen
0.12
-0.2%
Gold
1,710.63
-0.1%
Silver
20.73
+0.4%
Palladium
2,253.50
-0.4%
Platinum
929.00
+0.4%
Brent Crude
94.42
+1.1%
Top 40
59,101
-0.5%
All Share
65,484
-0.5%
Resource 10
63,360
+0.1%
Industrial 25
79,331
-0.9%
Financial 15
13,945
-0.4%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE